

Risk of myocarditis after mRNA COVID-19 vaccination vs after COVID-19 infection
Estimated cases of myocarditis by age, sex and vaccination status
Australia, October 2022

		Cases of myocarditis per million vaccine doses					
		Pfizer COVID-19 vaccine		Moderna COVID-19 vaccine			
Gender	Age group (years)	Post first dose	Post second or third dose	Post first dose	Post second or third dose	Post COVID-19 infection	Estimated myocarditis cases per million post COVID-19 vaccination or infection
Male	5-11	≤10	≤10	Insuff. data	Insuff. data	176	10 or less
	12-17	32	134	57	236	590	10.1 to 50
	18-29	23	94	56	232	637	50.1 to 100
	30-39	≤10	32	12	50	630	100.1 to 300
	40+	≤10	≤10	≤10	13	630	More than 300
Female	5-11	≤10	≤10	Insuff. data	Insuff. data	81	
	12-17	15	28	27	50	357	
	18-29	15	28	26	48	195	
	30-39	≤10	≤10	≤10	≤10	363	
	40+	≤10	≤10	≤10	11	363	

*****IMPORTANT NOTES*****

- Chart demonstrates risk of myocarditis following COVID-19 mRNA vaccination or infection. However, causality is not certain - i.e. rates above are inclusive of background myocarditis, which may be due to other causes.
- Calculations are based on population-level data and do not take into account individual risk factors including a past history of myocarditis following COVID-19 vaccine or infection
- Due to limitations in data availability, the risk of myocarditis following third doses of vaccine is assumed to approximate that following second doses.
- Due to limitations in data availability, the risk of myocarditis following vaccination with Moderna COVID-19 vaccine in children aged 5 to 11 years can not be estimated.
- Risk of myocarditis post COVID-19 infection assumes rates are consistent for all variants

Estimates based on CoRiCal (COVID-19 Risk Calculator):
<https://corical.immunisationcoalition.org.au>.
 Questions and feedback to:
corical.feedback@immunisationcoalition.org.au